UA84044U - Method for prediction of sensitivity to neoadjuvant therapy in breast cancer patients - Google Patents

Method for prediction of sensitivity to neoadjuvant therapy in breast cancer patients

Info

Publication number
UA84044U
UA84044U UAU201304135U UAU201304135U UA84044U UA 84044 U UA84044 U UA 84044U UA U201304135 U UAU201304135 U UA U201304135U UA U201304135 U UAU201304135 U UA U201304135U UA 84044 U UA84044 U UA 84044U
Authority
UA
Ukraine
Prior art keywords
breast cancer
sensitivity
prediction
cancer patients
neoadjuvant therapy
Prior art date
Application number
UAU201304135U
Other languages
Russian (ru)
Ukrainian (uk)
Inventor
Василий Федорович Чехун
Александр Владимирович Шепиль
Наталья Юрьевна Лукьянова
Светлана Владимировна Антипова
Original Assignee
Институт Экспериментальной Патологии, Онкологии И Радиобиологии Им. Р.Е. Кавецкого Нан Украины
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Институт Экспериментальной Патологии, Онкологии И Радиобиологии Им. Р.Е. Кавецкого Нан Украины filed Critical Институт Экспериментальной Патологии, Онкологии И Радиобиологии Им. Р.Е. Кавецкого Нан Украины
Priority to UAU201304135U priority Critical patent/UA84044U/en
Publication of UA84044U publication Critical patent/UA84044U/en

Links

Abstract

A method for predicting sensitivity to neoadjuvant therapy in patients with breast cancer with verified diagnosis consists in that prior to the first course of neoadjuvant chemotherapy in patients with breast cancer the level of serum ferritin is determined and ferritin values from 10 to 200 ng/ml predict sensitivity of tumors to neoadjuvant chemotherapy, and for values of ferritin levels 200 ng/ml - resistance to neoadjuvant chemotherapy.
UAU201304135U 2013-04-02 2013-04-02 Method for prediction of sensitivity to neoadjuvant therapy in breast cancer patients UA84044U (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
UAU201304135U UA84044U (en) 2013-04-02 2013-04-02 Method for prediction of sensitivity to neoadjuvant therapy in breast cancer patients

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
UAU201304135U UA84044U (en) 2013-04-02 2013-04-02 Method for prediction of sensitivity to neoadjuvant therapy in breast cancer patients

Publications (1)

Publication Number Publication Date
UA84044U true UA84044U (en) 2013-10-10

Family

ID=52283401

Family Applications (1)

Application Number Title Priority Date Filing Date
UAU201304135U UA84044U (en) 2013-04-02 2013-04-02 Method for prediction of sensitivity to neoadjuvant therapy in breast cancer patients

Country Status (1)

Country Link
UA (1) UA84044U (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114657246A (en) * 2022-02-18 2022-06-24 中山大学孙逸仙纪念医院 Marker for predicting neoadjuvant chemotherapy curative effect of non-metastatic breast cancer and application thereof

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114657246A (en) * 2022-02-18 2022-06-24 中山大学孙逸仙纪念医院 Marker for predicting neoadjuvant chemotherapy curative effect of non-metastatic breast cancer and application thereof
CN114657246B (en) * 2022-02-18 2023-05-12 中山大学孙逸仙纪念医院 Marker for predicting curative effect of non-metastatic breast cancer neoadjuvant chemotherapy and application thereof

Similar Documents

Publication Publication Date Title
BR112017009159A2 (en) methods and biomarkers to predict efficacy and evaluation of ox40 agonist treatment
PH12016500331A1 (en) Survival benefit in patients with solid tumors with elevated c-reactive protein levels
MY188938A (en) Therapeutic, diagnostic and prognostic methods for cancer of the bladder
MX2018008421A (en) Methods for treating cancer and the use of biomarkers as a predictor of clinical sensitivity to therapies.
MX343801B (en) Blood plasma biomarkers for bevacizumab combination therapies for treatment of breast cancer.
GB2545361A (en) Protein biomarker panels for detecting colorectal cancer and advanced adenoma
MA39776A (en) Cancer treatment with c-met antagonists and correlation of the latter with hgf expression
MX368099B (en) Biomarkers for predicting and assessing responsiveness of endometrial cancer subjects to lenvatinib compounds.
MY172580A (en) Tumor tissue based biomarkers for bevacizumab combination therapies
MX2016012697A (en) Protein biomarker profiles for detecting colorectal tumors.
AR089067A1 (en) BIOMARKERS IN THE SANGUINEO PLASMA FOR BEVACIZUMAB COMBINATION THERAPIES FOR THE TREATMENT OF CANCER DE MAMA
EP3004394A4 (en) Assays, methods and kits for analyzing sensitivity and resistance to anti-cancer drugs, predicting a cancer patient's prognosis, and personalized treatment strategies
TR201909951T4 (en) A method for predicting the outcome of aflibercept treatment of a patient suspected of having cancer.
MX2021002014A (en) Predicting breast cancer recurrence.
MX339427B (en) Blood plasma biomarkers for bevacizumab combination therapies for treatment of pancreatic cancer.
MX2018005867A (en) Integration of tumor characteristics with breast cancer index.
BR112014018374A8 (en) METHOD FOR PREDICTING THE RESPONSE OF A PATIENT WITH CANCER, KIT, ANTIBODY, METHOD FOR THE TREATMENT OF CANCER AND PHARMACEUTICAL COMPOSITION
MX363845B (en) Caix stratification based cancer treatment.
MX363679B (en) Method of diagnosing cancer.
BR112015020054A2 (en) METHOD OF DETECTING RESISTANCE TO THE THERAPEUTIC EFFECTS OF AN AKT INHIBITOR IN A CANCER CELL
MX371426B (en) Method for predicting the onset of extrapyramidal symptoms (eps) induced by an antipsychotic-based treatment.
UA84044U (en) Method for prediction of sensitivity to neoadjuvant therapy in breast cancer patients
WO2015181555A8 (en) Expression profiling for determining the responsiveness of cancers to treatment with an anti-angiogenic agent
MX2017006201A (en) Predicting response to a vegf antagonist.
EA201501095A1 (en) EFFECTIVE TREATMENT OF NSCLC AND A PREDICTIVE CLINICAL MARKER OF SENSITIVE TREATMENT TO TUMOR